Afanat (Afatinib) 40 mg
Afanat 40 mg is an advanced targeted therapy drug. Active ingredient: Afatinib (40 mg).
Manufacturer: Natco Pharma (India). A generic version of the brand-name drug Giotrif / Gilotrif.
Why is Afatinib superior?
Unlike first-generation inhibitors (reversible binding), Afanat creates an irreversible bond with the cancer cell receptors. It blocks the entire ErbB family (EGFR, HER2, ErbB4), shutting down the signaling pathways that cancer cells use to grow and survive. This mechanism offers broader control over the tumor.
✅ Patient Outcome: Significant progression-free survival in patients with specific lung cancer mutations.
Indicated for the treatment of Non-Small Cell Lung Cancer (NSCLC):
- EGFR Mutation-Positive NSCLC: First-line treatment for patients with metastatic NSCLC whose tumors have non-resistant EGFR mutations (Exon 19 deletions or Exon 21 L858R substitution).
- Squamous NSCLC: For patients progressing after platinum-based chemotherapy.
Dosage: 1 tablet (40 mg) once daily.
⚠️ CRITICAL ABSORPTION WARNING (Food Interaction):
Food significantly blocks the absorption of the drug into your blood. Taking it with food renders the therapy ineffective.
- 🚫 DO NOT: Take with food.
- ✅ EMPTY STOMACH RULE: Take the tablet at least 1 hour before a meal OR 3 hours after a meal.
- Tip: Establish a routine, e.g., take it immediately upon waking up, wait one hour, then have breakfast.
- Severe hepatic (liver) or renal (kidney) impairment.
- Pregnancy and breastfeeding.
- Interstitial Lung Disease (ILD).
- Children and adolescents under 18.
- Severe intolerance to galactose.
Side effects are common but manageable with proactive care:
- Diarrhea: Very common. Patients should have anti-diarrheal medication (Loperamide) ready and start it at the first sign.
- Rash / Acne: Keep skin moisturized and use sunscreen. Often indicates the drug is effective.
- Stomatitis: Mouth sores.
- Paronychia: Nail bed infections.
What Customers Say
No reviews yet
Your review can be the first!